To review the pharmacologic and clinical trial data of the Food and Drug Administration–approved phosphodiesterase 5 (PDE5) inhibitors for the treatment of erectile dysfunction (ED).
DATA SOURCES
Primary research and review articles were identified through a search of ScienceDirect, PubMed/MEDLINE, and International Pharmaceutical Abstracts (1990–August 2004). The following search terms were used in the Medicine Dentistry and Pharmacology, Toxicology, and Pharmaceutical Sciences subcategories: phosphodiesterase 5 inhibitor, PDE5 inhibitor, erectile dysfunction, sildenafil, vardenafil, tadalafil, prostatectomy, and diabetes. Web of Science (1990–August 2004) was used to search for additional abstracts using the same search terms as above. The package inserts for sildenafil, vardenafil, and tadalafil were also consulted.
STUDY SELECTION AND DATA EXTRACTION
All identified research, review articles, and abstracts were assessed for relevance, and all relevant information was included. Priority was given to the primary medical literature and clinical trial reports.
DATA SYNTHESIS
ED is a common disorder in males with increased prevalence associated with age and presence of cardiovascular disease, prostatectomy, or diabetes mellitus. Sildenafil, vardenafil, and tadalafil are selective PDE5 inhibitors currently available for treatment of ED. Their pharmacology and pharmacokinetics vary slightly, but with potentially important clinical differences in duration of activity; all have similar clinical efficacy and adverse effect profiles in patients with ED of various causes.
CONCLUSIONS
Sildenafil, vardenafil, and tadalafil are safe and effective PDE5 inhibitors for the treatment of ED.
. NIH Consensus Conference. Impotence: NIH Consensus Development Panel on Impotence. JAMA1993; 270: 83–90.
2.
. KorenmanSG. Epidemiology of erectile dysfunction. Endocrine2004; 23: 87–91.
3.
. FeldmanHA, GoldsteinI, HatzichristouDG, KraneRJ, McKinlayJB. Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study. J Urol1994; 151: 54–61.
4.
. SiegelT, MoulJW, SpevakM, AlvordWG, CostabileRA. The development of erectile dysfunction in men treated for prostate cancer. J Urol2001; 165: 430–5.
5.
. StockRG, KaoJ, StoneNN. Penile erectile function after permanent radioactive seed implantation for treatment of prostate cancer. J Urol2001; 165: 436–9.
6.
. FeldmanHA, JohannesCB, DerbyCA, KleinmanKP, MohrBA, AraujoAB, McKinlayJB. Erectile dysfunction and coronary risk factors: prospective results from the Massachusetts Male Aging Study. Prev Med2000; 30: 328–38.
7.
. GoldsteinI. The mutually reinforcing triad of depressive symptoms, cardiovascular disease, and erectile dysfunction. Am J Cardiol2000; 86: 41F–5F.
8.
. KandeelFR, KoussaVK, SwerdloffRS. Male sexual function and its disorders: physiology, pathophysiology, clinical investigation, and treatment. Endocr Rev2001; 22: 342–88.
9.
. GresserU, GleiterCH. Erectile dysfunction: comparison of efficacy and side effects of the PDE-5 inhibitors sildenafil, vardenafil and tadalafil: review of the literature. Eur J Med Res2002; 7: 435–46.
10.
. FingerWW, LundM, SlagleMA. Medications that may contribute to sexual disorders. A guide to assessment and treatment in family practice. J Fam Pract1997; 44: 33–43.
11.
. BrockGB, LueTF. Drug-induced male sexual dysfunction: an update. Drug Saf1993; 8: 414–26.
12.
. BansalS. Sexual dysfunction in hypertensive men: a critical review of the literature. Hypertension1988; 12: 1–10.
13.
. BurnhamTH, WickershamRM, NovakKK, eds. Drug facts and comparisons. St. Louis, MO: Facts and Comparisons, 2004.
14.
. PrisantLM, CarrAA, BottiniPB, SolurshDS, SolurshLP. Sexual dysfunction with antihypertensive drugs. Arch Intern Med1994; 154: 730–6.
15.
. BarksdaleJD, GardnerSF. The impact of first-line antihypertensive drugs on erectile dysfunction. Pharmacotherapy1999; 19: 573–81.
16.
. MitchellJE, PopkinMK. Antidepressant drug therapy and sexual dysfunction in men: a review. J Clin Psychopharmacol1983; 3: 76–9.
17.
. MitchellJE, PopkinMK. Antipsychotic drug therapy and sexual dysfunction in men. Am J Psychiatry1982; 139: 633–7.
18.
. ClaytonAH, PradkoJF, CroftHA, MontanoCB, LeadbetterRA, Bolden-WatsonC, Prevalence of sexual dysfunction among newer antidepressants. J Clin Psychiatry2002; 63: 357–366.
19.
. FavaM, RankinM. Sexual functioning and SSRIs. J Clin Psychiatry2002; 63 (suppl 5): 13–6.
20.
. KennedySH, McCannSM, MasellisM, McIntyreRS, RaskinJ, McKayG, Combining bupropion SR with venlafaxine, paroxetine, or fluoxetine: a preliminary report on pharmacokinetic, therapeutic, and sexual dysfunction effects. J Clin Psychiatry2002; 63: 181–6.
21.
. RosenRC, KostisJB. Overview of phosphodiesterase 5 inhibition in erectile dysfunction. Am J Cardiol2003; 92 (suppl): 9M–18M.
22.
. CroweSM, StreetmanDF. Vardenafil treatment for erectile dysfunction. Ann Pharmacother2004; 38: 77–85. DOI 10.1345/aph.1D019
23.
. BoolellM, AllenMJ, BallardSA, Gepi-AtteeS, MuirheadGJ, NaylorAM, Sildenafil: an orally active type 5 cyclic GMP-specific phosphodiesterase inhibitor for the treatment of penile erectile dysfunction. Int J Impot Res1996; 8: 47–52.
24.
. MeulemanE. Review of tadalafil in the treatment of erectile dysfunction. Exp Opin Pharmacother2003; 4: 2049–56.
. Cialis (tadalafil) prescribing information. www.cialis.com (accessed 2004 May 26).
31.
. CheitlinMD, HutterAM, BrindisRG, GanzP, KaulS, RussellROJ, ACC/AHA expert consensus document. Use of sildenafil (Viagra) in patients with cardiovascular disease. American College of Cardiology/American Heart Association. J Am Coll Cardiol1999; 33: 273–82.
32.
. KeatingGM, ScottLJ. Vardenafil: a review of its use in erectile dysfunction. Drugs2003; 63: 2673–703.
33.
. PomerolJM, RabassedaX. Tadalafil, a further innovation in the treatment of sexual dysfunction. Drugs Today2003; 39: 103–13.
34.
. WebbDJ, MuirheadGJ, WulffM, JA SuttonJA, R. LeviR, DinsmoreWW. Sildenafil citrate potentiates the hypotensive effects of nitric oxide donor drugs in male patients with stable angina. J Am Coll Cardiol2000; 36: 25–31.
35.
. SetterSM, BakerDE, CampbellRK, JohnsonSB. Sildenafil (Viagra) for the treatment of erectile dysfunction. Diabetes Educator1999; 25: 79–89.
36.
. RosenRC, McKennaKE. PDE-5 inhibition and sexual response: pharmacological mechanisms and clinical outcomes. Annu Rev Sex Res2002; 3: 36–88.
. SussmanDO. Pharmacokinetics, pharmacodynamics, and efficacy of phosphodiesterase type 5 inhibitors. J Am Osteopath Assoc2004; 104 (suppl 4): S11–5.
39.
. PollackCV, GiblerBW. 2000 ACC/AHA guidelines for the management of patients with unstable angina and non–ST-segment elevation myocardial infarction: a practical summary for emergency physicians. Ann Emerg Med2001; 38: 229–40.
40.
. RohdeG, WensingG, UngerS, SachseR. The pharmacokinetics of vardenafil, a new selective PDE5 inhibitor, is minimally affected by coadministration with cimetidine or ranitidine (abstract). Pharmacotherapy2001; 21: 1254.
41.
. BrockGB, McMahonCG, ChenKK. CostiganT, ShenW, WatkinsV, Efficacy and safety of tadalafil for the treatment of erectile dysfunction: results of integrated analyses. J Urol2002; 168: 1332–6.
42.
. StreidleC, FeldmanR, LetteiriJ, Pharmacokinetics of vardenafil (a new selective PDE5 inhibitor) in the elderly and subgroup data on efficacy and safety in elderly patients with erectile dysfunction (abstract). Presented at: Annual Meeting of the American Geriatrics Society, Chicago, May 9–13, 2001.
43.
. SteidleC P, FeldmanR, LettieriJ, AgarwalV, SegersonT. Pharmacokinetics of vardenafil (a new selective PDE5 inhibitor) in the elderly and subgroup data on efficacy and safety in elderly patients with erectile dysfunction (abstract). J Am Geriatr Soc2001; 49: S103.
44.
. PryorJ. Vardenafil: update on clinical experience. Int J Impot Res2002; 14 (suppl 1): S65–9.
45.
. BrindisRG, KlonerRA. Sildenafil in patients with cardiovascular disease. Am J Cardiol2003; 92 (suppl): 26M–36M.
46.
. KlonerRA, MitchellM, EmmickJT. Cardiovascular effects of tadalafil in patients on common antihypertensive therapies. Am J Cardiol2003; 92 (suppl): 47M–57M.
47.
. HerschornS. Cardiovascular safety of PDE5 inhibitors. Can J Urol2003; 10 (suppl 1): 23–8.
48.
. KlonerRA, MitchellM, EmmickJT. Cardiovascular effects of tadalafil. Am J Cardiol2003; 92 (suppl): 37M–46M.
49.
. GoldsteinI, LueTF, Padma-NathanH, RosenRC, SteersWD, WickerPA. Oral sildenafil in the treatment of erectile dysfunction. New Eng J Med1998; 338: 1397–404.
50.
. Padma-NathanH, SteersWD, WickerPA. Efficacy and safety of oral sildenafil in the treatment of erectile dysfunction: a double-blind, placebo-controlled study of 329 patients. Int J Clin Pract1998; 52: 375–9.
51.
. FagelmanE, FagelmanA, ShabsighR. Efficacy, safety, and use of sildenafil in urologic practice. Urology2001; 57: 141–4.
52.
. LewisR, BennettCJ, BorkonWD, BoykinWH, AlthofSE, StecherVJ et al. Patient and partner satisfaction with Viagra (sildenafil citrate) treatment as determined by the erectile dysfunction inventory of treatment satisfaction questionnaire. Urology2001; 57: 960–5.
53.
. RendellMS, RajferJ, WickerPA, SmithMD. Sildenafil for treatment of erectile dysfunction in men with diabetes: a randomized controlled trial. Sildenafil Diabetes Study Group. JAMA1999; 281: 421–6.
54.
. El-SakkaAI. Efficacy of sildenafil citrate in treatment of erectile dysfunction: effect of type 2 diabetes. Eur Urol2004; 46: 503–9. DOI 10.1016/j.eururo.2004.06.005
55.
. PorstH, RosenR, Padma-NathanH, GoldsteinI, GiulianoF, UlbrichE, The efficacy and tolerability of vardenafil, a new selective phosphodiesterase type 5 inhibitor, in patients with erectile dysfunction: the first at-home clinical trial. Int J Impot Res2001; 13: 192–9.
56.
. PorstH, YoungJM, SchmidtAC, BuvatJ; Vardenafil Study Group. Efficacy and tolerability of vardenafil for treatment of erectile dysfunction in patient subgroups. Urology2003; 62: 519–23.
57.
. PotempaA, UlbrichE, BernardI, BenekeM; Vardenafil Study Group. Efficacy of vardenafil in men with erectile dysfunction: a flexible-dose community practice study. European Urology2004; 46: 73–9.
58.
. HatzichristouD, FrancescoF, BuvatJ, LaferriereN, BandelTJ, PorstH; European Vardenafil Study Group. The efficacy and safety of flexible-dose vardenafil (Levitra) in a broad population of European men. European Urology2004; 45: 634–41.
59.
. HellstromWJG, GittelmanM, KarlinG, SegersonT, ThibonnierM, TaylorT, Sustained efficacy and tolerability of vardenafil, a highly potent selective phosphodiesterase type 5 inhibitor, in men with erectile dysfunction: results of a randomized, double-blind, 26-week placebo-controlled pivotal trial. Urology2003; 61 (suppl 1): 8–14.
60.
. RosenRC, Padma-NathanH, ShabsighR, SaikaliK, WatkinsV, PullmanWE. Cialis (IC351) provides prompt response and extended period of responsiveness for the treatment of men with erectile dysfunction (abstract). J Urol2001; 165 (suppl): 224.
61.
. BrockGB, McMahonCG, ChenKK, CostiganT, ShenW, WatkinsV, Efficacy and safety of tadalafil for the treatment of erectile dysfunction: results of integrated analyses. J Urol2002; 168: 1332–6.
62.
. PorstH, Padma-NathanH, GiulianoF, AnglinG, VaraneseL, RosenR. Efficacy of tadalafil for the treatment of erectile dysfunction at 24 and 36 hours after dosing: a randomized controlled trial. Urology2003; 62: 121–5.
63.
. SkoumalR, ChenJ, KulaK, BrezaJ, CalomfirescuN, BassonBR, Efficacy and treatment satisfaction with on-demand tadalafil (Cialis) in men with erectile dysfunction. Eur Urol2004; 46: 362–9.
64.
. MontorsiF, VerheydenB, MeulemanE, JunemannKP, MoncadaI, ValiquetteL, Long-term safety and tolerability of tadalafil in the treatment of erectile dysfunction. Eur Urol2004; 45: 339–45.
65.
. GoldsteinI, YoungJM, FischerJ, BangerterK, SegersonT, TaylorT; Vardenafil Study Group. Vardenafil, a new phosphodiesterase type 5 inhibitor, in the treatment of erectile dysfunction in men with diabetes: a multicenter double-blind placebo-controlled fixed-dose study. Diabetes Care2003; 26: 777–83.
66.
. Saenz de TejadaI, AnglinC, KnightJR, EmmickJT. Effects of tadalafil on erectile dysfunction in men with diabetes. Diabetes Care2002; 25: 2159–64.
67.
. PerimenisP, MarkouS, GyftopoulosK, AthanasopoulosA, GiannitsasK, BarbaliasG. Switching from long-term treatment with self-injections to oral sildenafil in diabetic patients with severe erectile dysfunction. Eur Urol2002; 41: 387–91.
68.
. SafarinejadMR. Oral sildenafil in the treatment of erectile dysfunction in diabetic men: a randomized double-blind and placebo-controlled study. J Diabetes Complications2004; 8: 205–10.
69.
. BrockG, TaylorT, SegerM, for the Vardenafil PROSPECT Group. Efficacy and tolerability of vardenafil in men with erectile dysfunction following radical prostatectomy (abstract). Eur Urol2002; 1: 52.
70.
. RainaR, LakinMM, AgarwalA, Long-term effect of sildenafil citrate on erectile dysfunction after radical prostatectomy: 3-year follow-up. Urology2003; 62: 110–5.
71.
. RainaR, LakinMM, AgarwalA, SharmaR, GoyalKK, MontagueDK, Efficacy and factors associated with successful outcome of sildenafil citrate use for erectile dysfunction after radical prostatectomy. Urology2004; 63: 960–6.
72.
. RainaR, LakinMM, AgarwalA, MaschaE, MontagueDK, KleinE, Long-term intracavernous therapy responders can potentially switch to sildenafil citrate after radical prostatectomy. Urology2004; 63: 532–7.
73.
. ZagajaG P, MhoonDA, AikensJE, BrendlerCB. Sildenafil in the treatment of erectile dysfunction after radical prostatectomy. Urology2000; 56: 631–4.
74.
. ZippeCD, JhaveriFM, KleinEA, KediaS, PasqualottoFF, KediaA, Role of Viagra after radical prostatectomy. Urology2000; 55: 241–5.
75.
. MontorsiF, NathanHP, McCulloughA, BrockGB, BroderickG, AhujaS, Tadalafil in the treatment of erectile dysfunction following bilateral nerve sparing radical retropubic prostatectomy: a randomized, double-blind, placebo controlled trial. J Urol2004; 172: 1036–41.
